Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Morano F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C. Antoniotti C, et al. Among authors: rossini d. Clin Cancer Res. 2023 Jun 13;29(12):2291-2298. doi: 10.1158/1078-0432.CCR-22-3878. Clin Cancer Res. 2023. PMID: 37022350 Clinical Trial.
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Borelli B, Conca V, Carullo M, Sainato A, Mattioni R, Manfredi B, Balestri R, Buccianti P, Morelli L, Rossi P, Vagli P, Prete AA, Luca F, Morano F, Donato SD, Salvatore L, Bengala C, Rossini D, Boni L, Antoniotti C, Cremolini C, Masi G, Moretto R. Borelli B, et al. Among authors: rossini d. Clin Colorectal Cancer. 2023 Sep;22(3):339-343.e3. doi: 10.1016/j.clcc.2023.06.002. Epub 2023 Jun 11. Clin Colorectal Cancer. 2023. PMID: 37429749 Clinical Trial.
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Borelli B, Crucitta S, Boccaccino A, Antista M, Antoniotti C, Marmorino F, Rossini D, Conca V, Germani MM, Provenzano L, Spagnoletti A, Leone AG, Cucchiara F, Pietrantonio F, Del Re M, Danesi R, Masi G, Cremolini C, Moretto R. Borelli B, et al. Among authors: rossini d. Tumori. 2023 Oct;109(5):481-489. doi: 10.1177/03008916221147944. Epub 2023 Jan 6. Tumori. 2023. PMID: 36609197
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy.
Moretto R, Germani MM, Ros J, Daniel F, Ghelardi F, Vetere G, Giordano M, Toledo RA, Bergamo F, Randon G, Elez E, Lonardi S, Pietrantonio F, Vignali P, Rossini D, Matito J, Ugolini C, Fontanini G, Masi G, Cremolini C. Moretto R, et al. Among authors: rossini d. JCO Precis Oncol. 2023 Sep;7:e2300255. doi: 10.1200/PO.23.00255. JCO Precis Oncol. 2023. PMID: 37797285
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, Antoniotti C, Cupini S, Daniel F, Nasca V, Vetere G, Zaniboni A, Borelli B, Carullo M, Conca V, Passardi A, Tamburini E, Masi G, Pella N, Cremolini C. Fanotto V, et al. Among authors: rossini d. Cancers (Basel). 2023 Nov 16;15(22):5451. doi: 10.3390/cancers15225451. Cancers (Basel). 2023. PMID: 38001711 Free PMC article.
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
Dell'Aquila E, Rossini D, Fulgenzi CAM, Passardi A, Tamburini E, Vetere G, Carullo M, Citarella F, Antoniotti C, Zaniboni A, Pietrantonio F, Spagnoletti A, Marmorino F, Borelli B, Allegrini G, Lonardi S, Nappo F, Masi G, Cremolini C, Santini D. Dell'Aquila E, et al. Among authors: rossini d. ESMO Open. 2022 Dec;7(6):100606. doi: 10.1016/j.esmoop.2022.100606. Epub 2022 Oct 31. ESMO Open. 2022. PMID: 36327757 Free PMC article.
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, Napolitano S, Esposito L, Latiano TP, Maiello E, Del Re M, Lonardi S, Aprile G, Santini D, Masi G, Avallone A, Normanno N, Pietrantonio F, Pinto C, Ciardiello F, Cremolini C, Martinelli E. Martini G, et al. Among authors: rossini d. Cancer Med. 2023 Apr;12(8):9392-9400. doi: 10.1002/cam4.5699. Epub 2023 Mar 7. Cancer Med. 2023. PMID: 36880426 Free PMC article.
157 results